Ocrevus Approved in UK as First NHS Treatment for PPMS

Ocrevus Approved in UK as First NHS Treatment for PPMS

Publication date: May 13, 2019

This means that PPMS patients living in the U. K. will now have access to Ocrevus treatment through the country’s National Health Service (NHS). In the meantime, Genentech, a member of the Roche group – Ocrevus’ manufacturer – will work closely with the NHS in Wales and Northern Ireland, and the Scottish Medicines Consortium in Scotland, to ensure Ocrevus becomes available in all of the U. K. Ocrevus is the first approved NHS treatment for PPMS in the U. K., a landmark decision made possible only with the collective effort, and dedication, of MS support organizations, including the MS Trust, patients and physicians, a trust official said. The NHS in England now will have three months to prepare before it starts funding the treatment for all eligible PPMS patients receiving Ocrevus prescriptions from their doctors. The post Ocrevus Approved in UK as First NHS Treatment for PPMS appeared first on Multiple Sclerosis News Today.

Concepts Keywords
CEO Magnetic resonance imaging
David Martin MRI
England NHS England
Genentech PPMS
Magnetic Resonance Imaging Ocrelizumab
MRI Breakthrough therapy
Multiple Sclerosis Genentech
NHS Monoclonal antibodies
NHS England Multiple sclerosis
NHS Wales National Health Service
NICE Life sciences
Northern Ireland Articles
Progressive Health
Scotland Member theRoche
Survey

Semantics

Type Source Name
drug DRUGBANK Nonoxynol-9
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis
gene UNIPROT KCNIP3
pathway BSID Release
gene UNIPROT CYREN
disease MESH primary progressive multiple sclerosis
drug DRUGBANK Ocrelizumab
gene UNIPROT SLC35G1
disease DOID PPMS
gene UNIPROT NHS

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *